Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp416 | Steroid hormones and receptors | ECTS2014

Novel mechanisms of action and new target genes of the glucocorticoid receptor in inflammatory bone disease and bone loss

Baschant Ulrike , Ahmad Mubashir , Koenen Mascha , Knoll Jeanette , Culemann Stephan , Schauer Sebastian , Bauer Kerstin , Wittig-Blaich Stephanie , Rauch Alexander , Kronke Gehrhard , Dudeck Anne , David Jean-Pierre , Rauner Martina , Seibel Markus , Ploubidou Aspasia , Zhou Hong , Hofbauer Lorenz , Tuckermann Jan

Glucocorticoids (GCs) are widely used to treat chronic inflammatory diseases such as rheumatoid (RA) and lead to multiple side effects including glucocorticoid induced osteoporosis (GIO). Our work challenges the dogma that transrepression of pro-inflammatory genes by the glucocorticoid receptor (GR) is solely responsible for reducing inflammation, whereas transactivation of genes is causing side effects.Using conditional and function selective mutant mic...

ba0004oc5 | (1) | ICCBH2015

Bivariate analyses of BMD and lean mass in children identifies variants with novel pleiotropic effects across six BMD loci and in the TOM1L2 locus

Medina-Gomez Carolina , Kemp John P , Heppe Denise H M , Tobias Jon H , Hofman Albert , Carola Zillikens M , Uitterlinden Andre G , Jaddoe Vincent W V , Evans David M , Rivadeneira Fernando

Background: Lean and bone mass are heritable traits with high phenotypic correlation (rho=0.44), likely reflecting the underlying mechanical and biochemical interactions between tissues.Aim: Estimate the shared heritability (genetic correlation) of both traits in children and identify genetic determinants displaying pleiotropic effects on lean mass and bone mass accrual.Methods: Participants make part of two prospective po...

ba0005ht4 | (1) | ECTS2016

Vitamin D supplementation in pregnancy leads to greater bone mass in UK infants born during winter months: the MAVIDOS multicentre, randomised, double-blind, placebo-controlled trial

Cooper Cyrus , Harvey Nicholas , Bishop Nicholas , Kennedy Stephen , Papageorghiou Aris , Schoenmakers Inez , Fraser Robert , Gandhi Saurabh , D'Angelo Stefania , Crozier Sarah , Moon Rebecca , Arden Nigel , Dennison Elaine , Godfrey Keith , Inskip Hazel , Prentice Ann , Mughal Zulf , Eastell Richard , Reid David , Javaid Kassim

Maternal vitamin D status has been positively associated with infant bone mass in observational studies. We therefore evaluated whether 1000 IU/day cholecalciferol during pregnancy would lead to greater offspring bone mass at birth, in a UK, multicentre, randomised, double-blind, placebo-controlled trial (MAVIDOS, ISRCTN82927713).At 12 weeks’ gestation, pregnant women with a serum 25-hydroxyvitamin D [25(OH)D] 25-100 nmol/l were randomised to either...

ba0005cabs.oc3.4 | Oral Communications | ECTS2016

Anti-sclerostin treatment prevents multiple myeloma bone disease and reduces tumour burden

McDonald Michelle , Reagan Michaela , Terry Rachael , Pettitt Jessica , Le Lawrence , Mohanty Sindhu , Kramer Ina , Kneissel Michaela , Brooks Daniel , Cheng Tegan , Little David , Bouxsein Mary , Rosen Cliff , Ghobrial Irene , Croucher Peter

Multiple myeloma is characterized by extensive bone marrow tumour and destructive osteolytic lesions. Both increased bone resorption and suppressed bone formation result in lesions and pathological fractures. Anti-resorptive therapies prevent further bone loss but patients continue to fracture, arguing for new therapies which increase bone strength. Anti-Sclerostin (Anti-Scl) is a potent stimulator of bone formation, is currently in clinical trials for osteoporosis, however it...

ba0005p483 | Paediatric bone disease | ECTS2016

Loss of type I collagen telopeptide lysyl hydroxylation causes musculoskeletal abnormalities in a zebrafish model of Bruck syndrome

Willaert Andy , Ghistelinck Charlotte , Witten P Eckhard , Huysseune Ann , Simoens Pascal , Symoens Sofie , Malfait Fransiska , De Muynck Amelie , De Paepe Anne , Kwon Ronald Y , Weiss Mary Ann , Eyre David E , Coucke Paul

Bruck syndrome, a disorder caused by bi-allelic mutations in either PLOD2 or FKBP10, is characterized by flexion contractures and bone fractures and shows strong clinical overlap with the brittle bone disease Osteogenesis Imperfecta. PLOD2 encodes the Lysyl hydroxylase 2 (LH2) enzyme, which is responsible for the hydroxylation of lysine residues in the type-I collagen telopeptides. This hydroxylation directs cross-linking of the collagen fibrils in t...

ba0005lb9 | (1) | ECTS2016

First X-linked form of osteogenesis imperfecta, caused by mutations in MBTPS2, demonstrates a fundamental role for regulated intramembrane proteolysis in normal bone formation

Lindert Uschi , Cabral Wayne , Ausavarat Surasawadee , Tongkobpetch Siraprapa , Ludin Katja , Barnes Aileen , Yeetong Patra , Weis Maryann , Krabichler Birgit , Makareeva Elena , Janecke Andreas , Leikin Sergey , Rothlisberger Benno , Rohrback Marianne , Kennerknecht Ingo , Eyre David , Suphapeetiporn Kanya , Giunta Cecilia , Marini Joan , Shotelersuk Vorasuk

Osteogenesis imperfecta (OI) is a heritable bone dysplasia with collagen-related defects. Dominantly inherited OI is caused by structural defects in type I collagen or IFITM5, while recessive forms are caused by deficiency of proteins that interact with collagen for modification, folding or cross-linking. We have identified the first X-linked form of OI, caused by a defect in regulated intramembrane proteolysis (RIP). One type of RIP involves sequential cleavage of regulatory ...

ba0007oc9 | (1) | ICCBH2019

Efficacy and safety of intravenous zoledronic acid for the treatment of pediatric glucocorticoid-induced osteoporosis: An international, randomized placebo-controlled trial

Ward Leanne M , Alos Nathalie , Cabral David A , Rodd Celia , Sbrocchi Anne Marie , Padidela Raja , Shaw Nick , Kostik Mikhail , Alexeeva Ekaterina , Thandrayen Kebashni , Aftring Paul , Choudhury Anup , Sunkara Gangadhar , Sayyed Sarfaraz , Munns Craig F.

Objectives: We evaluated the efficacy and safety of intravenous zoledronic acid (IV ZA) in children with glucocorticoid-induced osteoporosis (GIOP) through a randomized, placebo (PBO)-controlled trial.Methods: In this multi-national Phase 3 trial (NCT00799266), children 5–17 years of age with GIOP and low-trauma vertebral fractures (VF) were randomized 1:1 to IV ZA 0.05 mg/kg or IV PBO every six months for one year. Changes in lumbar spine areal bon...

ba0007p151 | (1) | ICCBH2019

The safety and efficacy of denosumab versus zoledronic acid in the treatment of pediatric osteoporosis: a randomized controlled pilot trial

Robinson Marie-Eve , Ma Jinhui , Khan Nasrin , Khatchadourian Karine , Page Marika , Konji Victor , Ann Matzinger Mary , Shenouda Nazih , Jaremko Jacob L , Zuijdwijk Caroline , Jackowski Stefan , Saleh David , MacLeay Lynn , Siminoski Kerry , Ward Leanne M

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Given its convenient mode of administration, our goal was to assess the safety and efficacy of Dmab compared to intravenous zoledronic acid (ZA) in pediatric osteoporosis.Methods: In this one-year pilot study (NCT02632916), children 4–16 years with low-trauma fractures due to osteoporosis were randomized 1:1 to receive ZA 0.025 mg/kg or Dma...

ba0007p152 | (1) | ICCBH2019

An evaluation of the rebound phenomenon during denosumab therapy in children with low turnover osteoporosis

Robinson Marie-Eve , Ma Jinhui , Khan Nasrin , Khatchadourian Karine , Page Marika , Konji Victor , Ann Matzinger Mary , Shenouda Nazih , Jaremko Jacob L , Zuijdwijk Caroline , Jackowski Stefan , Saleh David , MacLeay Lynn , Siminoski Kerry , Ward Leanne M

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Recent reports have raised concern about the ‘rebound phenomenon’ (hypercalcemia and increases in bone turnover markers, BTM) following Dmab in adults, and during treatment in children with osteogenesis imperfecta. The purpose of this report was to explore this phenomenon in children with osteoporosis associated with lower bone turnover.<p class="abstext...